RDY

Business Context and Reporting Period

This Form 6-K filing by Dr. Reddy's Laboratories Limited covers the period of March to April 2015. The document primarily disseminates two press releases regarding strategic partnerships and acquisitions aimed at expanding the company's footprint in the Indian pharmaceutical market, specifically in Hepatitis C treatment and established therapeutic brands.

Key Financial Metrics and Transactions

The filing does not provide consolidated revenue, profit, cash flow, or margin data for the reporting period. However, it details specific financial terms for a material acquisition:

• Acquisition Price: INR 800 Crores (approximately Euro 118 Million) for the select portfolio of UCB's established products business in India, Nepal, Sri Lanka, and Maldives.
• Target Revenue: The acquired business generated approximately INR 150 Crores in revenue for calendar year 2014.
• Workforce: The transaction includes approximately 350 employees.
• Liquidity and Debt: The filing text does not provide clear values for the company's overall debt levels, liquidity position, or cash flow status.

Material Changes and Strategic Developments

Two significant corporate actions were announced during this period:

1. Hepatitis C Partnership (March 23, 2015): Dr. Reddy's entered into an agreement with Hetero to license, distribute, and market Sofosbuvir 400 mg tablets (brand name Resof^TM) in India. This move targets the treatment of Chronic Hepatitis C, aiming to provide affordable access to a high-cure-rate regimen.
2. UCB Portfolio Acquisition (April 1, 2015): Dr. Reddy's signed a definitive agreement to acquire UCB's established products business in India. This acquisition strengthens Dr. Reddy's presence in Dermatology, Respiratory, and Pediatrics, adding market-leading brands such as Atarax, Nootropil, Zyrtec, and Xyzal.

Outlook, Risks, and Management Commentary

Management Commentary:

• CEO G V Prasad emphasized that the launch of Resof^TM aligns with the company's philosophy of "Innovative medicine at an affordable price," offering a high barrier to resistance and potential cures for Hepatitis C patients.
• Alok Sonig, Senior Vice President and India Business Head, stated the UCB acquisition will accelerate growth in high-growth therapeutic areas and welcomed the integration of UCB's employees.

• The UCB transaction is expected to close in the first quarter of the financial year 2015-16.
• The filing includes standard forward-looking statement disclaimers, noting risks related to general economic conditions, currency exchange rates, regulatory changes, competition, and integration issues associated with acquisitions.

Investor Verification Checklist

• Verify the closing date and final consideration for the UCB India portfolio acquisition.
• Monitor the commercial launch timeline and market uptake of Resof^TM in India.
• Assess the integration progress of the 350 employees and the acquired brands into Dr. Reddy's existing operations.
• Review subsequent quarterly reports for the impact of these transactions on consolidated revenue and margins.